These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12920419)

  • 1. Paroxetine-induced increase in metabolic end products of nitric oxide.
    Lara N; Archer SL; Baker GB; Le Mellédo JM
    J Clin Psychopharmacol; 2003 Aug; 23(4):408-12. PubMed ID: 12920419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxetine-induced increase in metabolic end products of nitric oxide.
    Lara N; Archer SL; Baker GB; Le Mellédo JM
    J Clin Psychopharmacol; 2003 Dec; 23(6):641-5. PubMed ID: 14624192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
    Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1451-3. PubMed ID: 19664676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder.
    Chrapko WE; Jurasz P; Radomski MW; Lara N; Archer SL; Le Mellédo JM
    Biol Psychiatry; 2004 Jul; 56(2):129-34. PubMed ID: 15231445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of response to paroxetine: influence of plasma level.
    Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma nitroso compounds are decreased in patients with endothelial dysfunction.
    Heiss C; Lauer T; Dejam A; Kleinbongard P; Hamada S; Rassaf T; Matern S; Feelisch M; Kelm M
    J Am Coll Cardiol; 2006 Feb; 47(3):573-9. PubMed ID: 16458138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
    Selley ML
    J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Obesity and endothelial dysfunction].
    Taddei S; Ghiadoni L; Salvetti G; Virdis A; Salvetti A
    G Ital Cardiol (Rome); 2006 Nov; 7(11):715-23. PubMed ID: 17216913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone half-life in a patient taking paroxetine -- a case report.
    Barnhill J; Susce MT; Diaz FJ; de Leon J
    Pharmacopsychiatry; 2005 Sep; 38(5):223-5. PubMed ID: 16189751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
    Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
    Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
    Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
    Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of sustained-release-L-arginine formulation on blood pressure and vascular compliance in 29 healthy individuals.
    Miller AL
    Altern Med Rev; 2006 Mar; 11(1):23-9. PubMed ID: 16597191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute exercise-induced nitric oxide production contributes to upregulation of circulating endothelial progenitor cells in healthy subjects.
    Yang Z; Wang JM; Chen L; Luo CF; Tang AL; Tao J
    J Hum Hypertens; 2007 Jun; 21(6):452-60. PubMed ID: 17344910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetition of ischemic preconditioning augments endothelium-dependent vasodilation in humans: role of endothelium-derived nitric oxide and endothelial progenitor cells.
    Kimura M; Ueda K; Goto C; Jitsuiki D; Nishioka K; Umemura T; Noma K; Yoshizumi M; Chayama K; Higashi Y
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1403-10. PubMed ID: 17446439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible paroxetine-induced symptomatic hypothyroidism.
    Takahashi M; Sawayama E; Sawayama T; Miyaoka H
    Pharmacopsychiatry; 2007 Sep; 40(5):201-2. PubMed ID: 17874352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.